Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome
Information source: Astellas Pharma Inc
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Urinary Tract Diseases
Intervention: Tamuslosin (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Astellas Pharma Inc Official(s) and/or principal investigator(s):
Study Director, Study Chair, Affiliation: Clinical Development, Astellas Pharma Inc.
Summary
The purpose of this study is to determine whether Tamuslosin is effective in the treatment of
lower urinary tract syndrome with female patients.
Clinical Details
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 20 Years.
Maximum age: 90 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Patients with urination disorder not accompanied by apparent organic or neurologic
abnormality(lower urinary tract syndrome: LUTs)．
Exclusion Criteria:
- Patients with urination disorder accompanied by apparent organic or neurologic
abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or
kidney complications.
Locations and Contacts
Hokkaido region, Japan
Touhoku region, Japan
Chubu region, Japan
Kinki region, Japan
Chugoku region, Japan
Kyushu region, Japan
Additional Information
Last updated: October 18, 2007
|
